Matrix metalloproteinase processing of CXCL11/I-TAC results in loss of chemoattractant activity and altered glycosaminoglycan binding
- PMID: 18411283
- DOI: 10.1074/jbc.M800266200
Matrix metalloproteinase processing of CXCL11/I-TAC results in loss of chemoattractant activity and altered glycosaminoglycan binding
Abstract
The CXCR3 chemokine receptor regulates the migration of Th1 lymphocytes and responds to three ligands: CXCL9/MIG, CXCL10/IP-10, and CXCL11/I-TAC. We screened for potential regulation of T cell responses by matrix metalloproteinase (MMP) processing of these important chemokines. The most potent of the CXCR3 ligands, CXCL11, was identified by matrix-assisted laser desorption ionization time-of-flight mass spectrometry as a substrate of the PMN-specific MMP-8, macrophage-specific MMP-12, and the general leukocyte MMP-9. The 73-amino acid residue CXCL11 is processed at both the amino and carboxyl termini to generate CXCL11-(5-73), -(5-63), and -(5-58) forms. NH2-terminal truncation results in loss of agonistic properties, as shown in calcium mobilization and chemotaxis experiments using CXCR3 transfectants and human T lymphocytes. Moreover, CXCL11-(5-73) is a CXCR3 antagonist and interestingly shows enhanced affinity to heparin. However, upon COOH-terminal truncation to position 58 there is loss of antagonist activity and heparin binding. Together this highlights an unexpected site for receptor interaction and that the carboxyl terminus is critical for glycosaminoglycan binding, an essential function for the formation of chemokine gradients in vivo. Hence, MMP activity might regulate CXCL11 tissue gradients in two ways. First, the potential of CXCL11-(5-73) to compete active CXCL11 from glycosaminoglycans might lead to the formation of an antagonistic haptotactic chemokine gradient. Second, upon further truncation, MMPs disperse the CXCL11 gradients in a novel way by proteolytic loss of a COOH-terminal GAG binding site. Hence, these results reveal potential new roles in down-regulating Th1 lymphocyte chemoattraction through MMP processing of CXCL11.
Similar articles
-
CXCR3 Ligands in Cancer and Autoimmunity, Chemoattraction of Effector T Cells, and Beyond.Front Immunol. 2020 May 29;11:976. doi: 10.3389/fimmu.2020.00976. eCollection 2020. Front Immunol. 2020. PMID: 32547545 Free PMC article. Review.
-
Expression and regulation of the CXCL9-11 chemokines and CXCR3 receptor in Atlantic salmon (Salmo salar).Front Immunol. 2024 Sep 5;15:1455457. doi: 10.3389/fimmu.2024.1455457. eCollection 2024. Front Immunol. 2024. PMID: 39301034 Free PMC article.
-
Small molecule chemokine mimetics suggest a molecular basis for the observation that CXCL10 and CXCL11 are allosteric ligands of CXCR3.Br J Pharmacol. 2012 Jun;166(3):912-23. doi: 10.1111/j.1476-5381.2011.01660.x. Br J Pharmacol. 2012. PMID: 21895630 Free PMC article.
-
Bu-Shen-Fang-Chuan formula attenuates T-lymphocytes recruitment in the lung of rats with COPD through suppressing CXCL9/CXCL10/CXCL11-CXCR3 axis.Biomed Pharmacother. 2020 Mar;123:109735. doi: 10.1016/j.biopha.2019.109735. Epub 2019 Dec 18. Biomed Pharmacother. 2020. PMID: 31864210
-
Review: The chemokine receptor CXCR3 and its ligands CXCL9, CXCL10 and CXCL11 in neuroimmunity--a tale of conflict and conundrum.Neuropathol Appl Neurobiol. 2010 Aug;36(5):368-87. doi: 10.1111/j.1365-2990.2010.01089.x. Epub 2010 May 6. Neuropathol Appl Neurobiol. 2010. PMID: 20487305 Review.
Cited by
-
A Novel Role of Matrix Metalloproteinase-8 in Macrophage Differentiation and Polarization.J Biol Chem. 2015 Jul 31;290(31):19158-72. doi: 10.1074/jbc.M114.634022. Epub 2015 Jun 19. J Biol Chem. 2015. PMID: 26092731 Free PMC article.
-
Matrix-metalloproteinases as targets for controlled delivery in cancer: An analysis of upregulation and expression.J Control Release. 2017 Aug 10;259:62-75. doi: 10.1016/j.jconrel.2017.01.034. Epub 2017 Jan 31. J Control Release. 2017. PMID: 28153760 Free PMC article. Review.
-
Targeting tumor cell motility as a strategy against invasion and metastasis.Trends Pharmacol Sci. 2013 May;34(5):283-9. doi: 10.1016/j.tips.2013.03.001. Epub 2013 Apr 6. Trends Pharmacol Sci. 2013. PMID: 23571046 Free PMC article. Review.
-
MMP-9 inhibition promotes anti-tumor immunity through disruption of biochemical and physical barriers to T-cell trafficking to tumors.PLoS One. 2018 Nov 30;13(11):e0207255. doi: 10.1371/journal.pone.0207255. eCollection 2018. PLoS One. 2018. PMID: 30500835 Free PMC article.
-
Structural determinant of BST-2-mediated regulation of breast cancer cell motility: a role for cytoplasmic tail tyrosine residues.Oncotarget. 2017 Nov 29;8(66):110221-110233. doi: 10.18632/oncotarget.22753. eCollection 2017 Dec 15. Oncotarget. 2017. PMID: 29299143 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous